Omni-Matrix K105 achieves 97.7% allele recovery in NFSTC independent validation — Read the study →
GeneLink™ Omni-Matrix™ K105 System

Trace DNA collection,
reimagined
at the source

A water-insoluble polymer matrix that physically captures surface-bound cells and cell-free DNA — then releases its full cargo during mechanical disruption. No irreversible substrate retention. No lost evidence.

Learn more
97.7% Allele recovery — blood on glass
15× Median yield vs. FLOQSwab
98.8% Mixed fingerprint recovery

Complete matrix release —
every cell, fully recovered

Conventional swabs impose a structural ceiling on DNA recovery: up to 76% of collected material remains irreversibly bound within the fiber matrix during extraction. The Omni-Matrix eliminates this ceiling. Sprayed onto smooth non-porous evidence surfaces, the polymer film incorporates all surface-bound cellular material. During mechanical disruption, the matrix releases its entire captured DNA cargo directly to extraction — with no irreversible substrate binding.

Water-insoluble polymer chemistry

Single-use 1 mL spray bottles apply a thin, even film from approximately 6 inches. The formulation is non-toxic and compatible with standard magnetic bead extraction systems including the Omni-Mag™ system.

Zero substrate-bound DNA loss

Unlike swabs, which require a spin-basket transfer step that permanently loses a fraction of captured DNA, the matrix releases its full captured cargo upon mechanical disruption — reducing both DNA loss and cross-contamination risk.

Validated collection workflow

Spray → allow 20 minutes to dry → scrape dried film with sterile plastic blade → transfer to extraction tube. Fully compatible with standard forensic laboratory workflows and capillary electrophoresis platforms.

In-field DNA protection

Once applied at the scene, the dried matrix film physically encapsulates surface-bound DNA, potentially protecting against degradation, UV exposure, and transit-related cellular loss during packaging.

Independent Validation

Two independent institutions.
Convergent evidence.

The NFSTC (2016) and Ramirez / John Jay College of Criminal Justice (2019) studies provide complementary validation from controlled glass substrates to real touch DNA on five forensically relevant mock evidence types.

97.7% Allele recovery — NFSTC 2016

Blood stains on glass at extreme 1:200 dilution. PurFlock® Ultra swab achieved only 27–39% at equivalent dilutions — directly relevant to trace casework concentrations.

98.8% Mixed fingerprint recovery — NFSTC 2016

Three-contributor mixed fingerprint on glass. A 24.8 percentage-point advantage over contemporary swab technology, directly reducing minor-contributor dropout risk.

15× Median DNA yield — Ramirez 2019

243.63 pg median vs. 16.64 pg for FLOQSwab from touch DNA on five non-porous mock evidence types. Statistically significant: Mann-Whitney U, p = 0.024.

52% Full / High Partial profiles — Ramirez 2019

Matrix samples yielded full or high partial GlobalFiler™ profiles in 52% of cases versus 24% for FLOQSwab — more than doubling CODIS-eligible upload rate.

17% Negative profile rate — vs. 44% for swab

Across five donors and five mock evidence types, Omni-Matrix reduced the negative (no donor alleles) profile rate from 44% to 17.4% — a 2.5× reduction in collection failure.

70.7% Median per-sample allele recovery

Compared with 2.6% median per-sample allele recovery for swab collection — a more-than-27-fold improvement in the proportion of expected alleles successfully recovered.

Applications

Where evidence cannot be lost

Validated for smooth non-porous surfaces across a range of forensic, biometric, and genomic applications where trace-level DNA collection is critical.

Forensic Investigation

Weapons, door handles, steering wheels, packaging, cable ties, masks, and digital devices. Superior allele recovery from touch deposits in the critical window between evidence collection and cold case degradation.

Immigration Control

Rapid biometric-grade DNA collection from identity documents, border hardware, and entry surfaces. Compatible with high-throughput microfluidic platforms for rapid field identification and database matching.

SNP Genotyping

15-fold median yield improvement enables SNP array and whole-genome sequencing from trace-level deposits previously below reliable amplification thresholds — expanding the genotyping landscape for low-template samples.

Mass Disaster Identification

Maximising DNA yield from degraded, contaminated, or low-transfer surfaces in mass casualty events. The closed-film collection mechanism reduces cross-contamination risk in multi-victim environments.

How It Works

Four steps.
Complete capture.

01

Spray

Apply Omni-Matrix K105 solution from approximately 6 inches onto the non-porous evidence surface. A uniform thin film forms as the polymer solution contacts the substrate, incorporating surface-bound cells and cell-free DNA.

02

Film formation

Allow approximately 20 minutes for the water-insoluble matrix to dry and fully encapsulate all surface DNA. The bright visible film aids documentation and confirms complete coverage of the sampling zone.

03

Collect

Scrape the dried film mechanically with a sterile plastic blade into a collection tube. The complete matrix is captured — no spin-basket, no transfer loss, no residual substrate-bound DNA.

04

Extract

The matrix releases its entire DNA cargo upon mechanical disruption, delivering it directly into lysis buffer. Compatible with Omni-Mag™ magnetic bead purification and standard downstream STR, SNP, and WGS workflows.

"The mechanistic explanation — complete physical release of captured DNA from the insoluble matrix during disruption, eliminating the substrate-bound DNA retention that limits all swab technologies — is well-supported by both studies."

Journal of Forensic Sciences, Trace DNA Collection Review — Omni-Matrix Section

Two independent institutions — the National Forensic Science Technology Center (NFSTC, 2016) and John Jay College of Criminal Justice (Ramirez, 2019) — using different substrates, deposit types, and experimental designs reached the same conclusion: the Omni-Matrix system substantially outperforms contemporary swab technology for trace DNA collection from smooth non-porous surfaces.

NFSTC Independent institutional validation, 2016. Glass substrates, blood dilution series and mixed fingerprints. PurFlock® Ultra swab comparator.
John Jay Peer-reviewed academic study, Ramirez (2019), CUNY. Five mock evidence types, five donors, IRB-approved. FLOQSwab comparator, GlobalFiler™ STR.
27× Improvement in median per-sample allele recovery over swab collection (70.7% vs 2.6%) across real touch DNA from five non-porous evidence types.
CODIS Matrix samples reached CODIS-upload threshold (≥8 core loci) at substantially higher rates, directly increasing investigative value of collected evidence.
Series A · $8M

Join Us in Transforming
Forensic DNA Collection

$8M Series A Raise 24–30 month runway
20–25% Equity Offered Pre-money: $24–32M
$160M–$560M Exit Valuation Year 5–7 target
Why invest now
  • NFSTC validation complete — scientific risk is retired
  • Granted US patent provides durable 20-year competitive moat
  • Forensic genomics moving irreversibly to ultra-low-template DNA
  • No competitor has an equivalent product — true first mover
$10.65B TAM — Global Forensic Tech
Entire addressable forensic technology market
$4B–6B SAM — Forensic DNA Consumables
Serviceable addressable market for DNA collection
$250M+ SOM — NGS + Touch DNA Niche
5.8% CAGR swab market to 2032 · Touch DNA now standard practice
18,000+ Law Enforcement Agencies
400+ US public forensic labs · US Military forensic units · International: UK, EU, Australia
Financial Projections

Break-Even Year 3 · 70–75% Gross Margin at Scale

Key assumptions: $1.50 ASP · $0.45 COGS at scale · 50,000 units/lab/yr · Beachhead: 150 labs by Yr 3 · 24–30 month runway on Series A

$1.50 ASP per unit

Average selling price at target volume. Low-cost consumable with high replacement rate per active lab.

75% Gross margin at scale

High-margin consumable model. Recurring revenue with low regulatory burden versus device classification.

$54M Year 5 revenue target

Projected from 150-lab beachhead in Yr 3 expanding through Federal, Military, and International phases.

$22M Year 5 EBITDA

Break-even at Year 3. 4–8× revenue multiple implies $160M–$560M exit valuation at target strategic acquirer.

$8M Series A —
24 to 30 Month Runway

Capital deployed across manufacturing scale-up, commercial launch, and validation milestones required for Federal and SWGDAM adoption.

Cap table post-Series A: Founders 60% · Series A 25% · Options 15%

$2.0M
Manufacturing Scale-UpGMP partner, tooling, quality systems
$2.0M
Sales & MarketingSales team, conferences, lab outreach
$1.5M
Clinical & Lab ValidationSWGDAM, beta lab program, FBI QAS
$1.5M
Working CapitalOperations, receivables, contingency
$1.0M
Regulatory & QualityISO 18385/13485 certification
Competitive Advantage

First-Mover with Granted Patent —
No Direct Competitors

Feature Cotton Swab Flocked Swab Omni-Matrix™
DNA Recovery 20–50% 40–60% ~100%
Release Efficiency Poor Moderate >95%
Trace DNA Performance Poor Moderate Excellent
Matrix Releases Completely No No Yes
Direct-to-Lysis No No Yes
NGS Compatible Limited Yes Optimized
Go-to-Market

High-Margin Consumable ·
Phased Market Entry · Strategic Exit

01 Yr 1–2

State Crime Labs

Direct sales to 400+ US crime labs. AAFS conferences. Beta with 3+ labs. SWGDAM validation.

02 Yr 2–3

Federal & Military

FBI QAS approval. DOD forensic units. Federal law enforcement contracts.

03 Yr 3–4

International

CE marking. UK, EU, Australia. Distributor partnerships.

04 Yr 4–5

OEM & Clinical

Rapid DNA platforms. SNP genomics, immigration screening, pharmacogenomics.

Strategic Exit Targets

Partnership· Licensing · Acquisation

4–8× Revenue → $160M–$560M implied valuation

Granted Patent —
~20 Year Protection Window

First-mover IP position with an issued US utility patent, additional device utility filings planned, and manufacturing process protected as trade secret.

US Patent No. 10,228,307 Issued March 2019 · BioFunctions, Inc.

Ali Javed, Ph.D

Director, Research & Development · BioFunctions, Inc.

ali.javed@biofunctions.com

Confidential — for accredited investor use only · US Patent 10,228,307 · BioFunctions, Inc.

© 2025 GeneLink Inc. Omni-Matrix™ is a trademark of GeneLink Inc.

For forensic laboratory and research use.